Patients‘ chances of survival after cancer surgery is strongly linked with the standard of post-operation hospital care, a major international study suggests.
A long-standing mystery is why fast-growing cells, like cancer cells and immune cells, rely on a seemingly inefficient form of metabolizing glucose to power their activities. In a new study, scientists now offer a compelling solution.
Scientists modify CAR T-Cell therapy, making it more effective and less toxic, for possible use in solid tumors such as neuroblastoma.
Treatment options for many types of cancers remain limited, due partly to the in vitro tools used to model cancers and that results from animal studies do not always translate well to human disease. These shortcomings point to a clear need for a better, patient-specific model. Researchers suggest bioengineered microscale organotypic models can address this need.
Researchers have developed a new integrated genetic/epigenetic DNA-sequencing protocol known as MultiMMR that can identify the presence and cause of mismatch repair (MMR) deficiency in a single test from a small sample of DNA in colon, endometrial, and other cancers. This alternative to complex, multi-step testing workflows can also determine causes of MMR deficiency often missed by current clinical tests.
As part of a clinical study, researchers are conducting a thorough and highly precise investigation into the molecular and functional properties of tumors. Their goal is to help physicians to better determine which treatment will best match every patient’s cancer and thus be most effective.
Study defines small-cell lung cancer subtypes and distinct therapeutic vulnerabilities for each type
Researchers have developed the first comprehensive framework to classify small-cell lung cancer (SCLC) into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type in a study.
Researchers have discovered a new enzymatic function of the Epstein-Barr Virus (EBV) protein EBNA1, a critical factor in EBV’s ability to transform human cells and cause cancer. Study provides new indications for inhibiting EBNA1 function, opening up fresh avenues for development of therapies to treat EBV-associated cancers.
Researchers have developed a predictive theory for tumor growth that approaches the subject from a new point of view. Rather than focusing on the biological mechanisms of cellular growth, the researchers instead use thermodynamics and the physical space the tumor is expanding into to predict its evolution from a single cell to a complex cancerous mass.
Scientists have found a way to prevent gold nanoparticles from clumping, which could help towards their use as an anti-cancer therapy.
A new study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma.
To better understand the conditions that select for the Warburg Effect and the mechanisms where cells can express this metabolic adaptation, researchers subjected nonmalignant cells to the harsh tumor microenvironment that is present during early carcinogenesis, known as ductal carcinoma in situ. In a new research article, the team shows that these conditions select for cells to express a Warburg Effect.
A look at RNA tells us what our genes are telling our cells to do, and scientists say looking directly at the RNA of brain tumor cells appears to provide objective, efficient evidence to better classify a tumor and the most effective treatments.
New research has demonstrated that a simple, cheap test can help identify who is at risk of developing colorectal cancer, aiding early diagnosis and potentially saving lives.
New computational tool reliably differentiates between cancer and normal cells from single-cell RNA-sequencing data
Researchers have developed a new computational tool to accurately differentiate between cancer cells and normal cells when analyzing large single-cell RNA-sequencing data.
Researchers find that CRY-1, a regulator of circadian rhythms, promotes tumor progression by altering DNA repair.
Researchers have found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.
Why do some hosts‘ immune systems reject tumors easily, while others have a harder time doing so? It depends on the types of the immune cells known as CD8 T cells and how a host’s specific T cells match up with the neoantigens present in the tumor.
For the first time, scientists have measured the different types of genomic DNA changes that occur in skin cells, finding that mutations from ultraviolet (UV) light is especially common, but Black individuals have lower levels of UV damage compared to white people.
Researchers took the novel approach of targeting specific cell proteins that control DNA information using inhibitors, or drugs, that were effective in reducing the growth of the Waldenström macroglobulinemia cancer cells and when combined with a third drug were even more successful in killing the WM cancer cells which could lead to more treatment options.
A new computational technique that uses heat map data to reverse engineer highly detailed models of chromosomes and researchers have uncovered new information about the close spatial relationships that chromatin folding creates between genes.
Engineers have developed in vitro — in the lab — lymphatic vessel model to study the growth of tumor emboli, collections of tumor cells within vessels that are often associated with increased metastasis and tumor recurrence.
In an article published in Cell Metabolism, Moffitt Cancer Center researchers report on a newly discovered biochemical pathway that protects cells from a type of cell death called ferroptosis.
Leading cancer expert solve long-standing question of how various types of mutations in just one gene cause different types of diseases.